Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2828360 · 1 trial · 1 indication
The weekly mean of the 24-Hour APS was calculated from participants' daily entries for 24-hour average pain rating on an 11-point scale with scores from 0 (no pain) to 10 (worst possible pain). Data were recorded twice a day at approximately the same time each day, preferably first thing in the morning and in the afternoon.
| Arm | Type | Description |
|---|---|---|
| LY2828360 then Placebo | EXPERIMENTAL | 80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments. |
| Placebo then LY2828360 | EXPERIMENTAL | Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments. |
| Name | Type | Description |
|---|---|---|
| LY2828360 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Are male or female participants with osteoarthritis (OA), as determined by medical history and physical examination. Males and females with stable medical problems that, in the investigator's opinion, will not significantly alter the disposition of the drug, will not place the...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
LY2828360 was studied for the treatment of knee osteoarthritis pain. It is an investigational small molecule developed by Eli Lilly and Company and has been evaluated in a Phase 2 clinical trial in patients with osteoarthritic knee pain. It is not described as an approved therapy.
LY2828360 targets CNR2, the cannabinoid receptor 2, and acts as an agonist at this receptor. CNR2 is a G protein-coupled receptor, and LY2828360 was designed to activate it as a small molecule drug candidate.
LY2828360 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating this compound.
LY2828360 reached Phase 2 clinical development. One Phase 2 trial has been completed, and no trials are currently listed as active. The compound is investigational and has not been described as approved for any indication.
LY2828360 was evaluated in the Phase 2 trial NCT01319929, titled A Study of LY2828360 in Patients With Osteoarthritic Knee Pain. The trial enrolled 39 patients, was randomized, double blind, and controlled, and was conducted in Denmark. It is now completed.